Servo Controlled Oxygen Targeting (SCO2T) Study: Masimo vs. Nellcor (SCO2T)
Premature, Premature Infant, Oxygen Therapy
About this trial
This is an interventional treatment trial for Premature focused on measuring Servo Control, Closed-Loop Automated Oxygen Control, Pulse oximeter technology
Eligibility Criteria
Inclusion Criteria:
- Infants born at less than 30 weeks gestation
- Infants greater than 48 hours of age
- Infants who are receiving supplementary oxygen
- Person with parental responsibility able to give consent
Exclusion Criteria:
- Congenital anomalies that would prevent targeting SpO2 to 90-95% (e.g. cardiac defects)
- Clinical condition of an infant would impair accurateTcPO2 measurement (e.g. impaired perfusion or requirement of inotropic or vasopressor support)
- Parent/person with parental responsibility unable to give informed consent on behalf of the infant
- Infants born less than 22 weeks gestation
Sites / Locations
- The Simpson Centre for Reproductive Health, Royal Infirmary EdinburghRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Servo control - Masimo oximetry technology (Oxygen Assist Module, IntellO2, Vapotherm)
Servo control - Nellcor oximetry technology (Oxygen Assist Module, IntellO2, Vapotherm)
Automated control of oxygen. The oxygen saturation target range will be set to 90-95% (set to maintain an integral value of 93%) as per standard clinical practice. Automated oxygen control can be overridden by manual adjustment of oxygen at any time if this is considered necessary to optimise control of oxygenation according to current clinical targets.
Automated control of oxygen. The oxygen saturation target range will be set to 90-95% (set to maintain an integral value of 93%) as per standard clinical practice. Automated oxygen control can be overridden by manual adjustment of oxygen at any time if this is considered necessary to optimise control of oxygenation according to current clinical targets.